Gulf Shipping Crisis Puts NHS Supply Chains at Risk

Where the supply chain breaks

The NHS has been placed on "high alert" over looming shortages and rising costs for medicines and medical products including syringes, intravenous bags, gloves and catheters, as reported by the Guardian. The cause is the Gulf shipping standstill, which has disrupted the flow of petrochemical feedstocks on which much of modern healthcare depends.

Gulf shipping routes, principally the Strait of Hormuz, carry around 20–25% of global oil trade. Prolonged disruption to these routes has historically driven polyethylene and polypropylene spot prices sharply higher within weeks, according to commodity market data. These two polymers are the base materials for the vast majority of sterile, single-use clinical consumables: PPE, IV tubing, syringe barrels, catheter housings and diagnostic-device casings.

The dependency extends beyond finished plastic goods. Active pharmaceutical ingredients (APIs) frequently rely on petrochemical precursors. When feedstock supply tightens, the effects cascade through every tier of the manufacturing chain, from bulk chemical producers in the Gulf and Asia to specialist compounders and contract manufacturers in Europe and the UK.

For the NHS, which spends roughly £7–8 billion annually on consumables and medical devices according to published procurement data, even modest feedstock price rises compound quickly. A 5–10% increase in polymer input costs can translate into significantly larger percentage increases at the finished-product level once processing, sterilisation, packaging and logistics margins are factored in.

Cost exposure for UK medical-device suppliers

The firms most immediately exposed are the UK-based SMEs and contract manufacturers that sit between petrochemical feedstock suppliers and the NHS procurement framework. These businesses typically operate on thin margins, often locked into fixed-price or capped-price contracts with NHS Supply Chain or individual trusts.

Several dynamics make their position precarious. First, most do not buy raw polymer directly from Gulf producers; they purchase from European distributors, adding an intermediary layer that amplifies price movements. Second, NHS procurement frameworks frequently include price-review mechanisms that lag the spot market by months, meaning suppliers absorb input cost increases long before they can renegotiate.

Third, many of these firms lack the balance-sheet depth to stockpile raw materials. Unlike large multinational device manufacturers, which may hold weeks or months of polymer inventory, smaller UK suppliers often run lean, just-in-time procurement models. That approach, efficient in stable markets, becomes a vulnerability when supply tightens and allocation constraints emerge.

The risk is not confined to price. If petrochemical feedstock becomes scarce, large global manufacturers will be prioritised by polymer suppliers, leaving smaller UK firms further down the allocation queue. The result could be an inability to fulfil NHS orders at any price.

Lessons not learned from the PPE scramble

The Covid-19 pandemic exposed the UK's lack of domestic manufacturing capacity for single-use medical products in stark terms. The scramble for PPE in 2020 led to widely criticised emergency procurement, billions of pounds in write-offs on substandard or unusable stock, and a national debate about the strategic importance of onshore production.

Promises of reshoring followed. Yet domestic capacity for medical-grade polymer conversion remains limited, as industry bodies have repeatedly noted. The UK still imports the majority of its single-use clinical consumables, with significant volumes originating from manufacturers in Asia and the Middle East that are themselves dependent on Gulf petrochemical supply.

Much of modern healthcare is dependent on the petrochemicals now held up by the Gulf shipping standstill, whether for active pharmaceutical ingredients or to produce the millions of sterile single-use items, ranging from PPE to catheters and diagnostic-device casings.

That assessment, from the Guardian's reporting on the NHS response, underscores how little the structural picture has changed since 2020. The UK remains a price-taker in global polymer markets and a net importer of finished medical goods. The Iran conflict has simply re-exposed a vulnerability that was already well documented.

For businesses outside healthcare, the broader signal is worth noting. Petrochemical dependency runs through sectors that rarely think of themselves as energy-exposed. Food packaging, veterinary supplies, laboratory consumables, automotive components and construction materials all share similar feedstock pathways. The Gulf disruption is a stress test for any business whose products begin life as a hydrocarbon.

What operators can do now

For UK medical-device suppliers and contract manufacturers, the window for action is narrow. Several operational steps merit immediate consideration.

Audit feedstock exposure

Firms should map their full polymer supply chain, identifying not just their direct suppliers but the origin of raw feedstock. Understanding whether inputs transit the Strait of Hormuz, or are processed in facilities that depend on Gulf crude, is essential for assessing true exposure.

Secure forward supply where possible

Where balance sheets permit, locking in polymer supply at current prices, even at a modest premium, may prove cheaper than buying on the spot market in four to six weeks. Firms with existing supplier relationships should be negotiating volume commitments now.

Engage NHS procurement teams early

Suppliers that wait until they cannot fulfil orders before raising the issue with NHS buyers will find themselves in the weakest possible negotiating position. Proactive communication about potential cost increases and lead-time extensions is both commercially prudent and contractually advisable under most framework agreements.

Explore alternative polymer sources

Not all medical-grade polyethylene and polypropylene originates from Gulf feedstock. North American shale-derived polymers and European recycled-content grades may offer partial substitution, though regulatory approval for medical-device applications can be a bottleneck.

Revisit inventory policy

The just-in-time model that dominates UK medical manufacturing was designed for a world of stable, liquid supply chains. That world has been disrupted twice in six years. Firms that build modest buffer stocks of critical polymer grades will be better positioned to weather both this crisis and the next.

None of these steps eliminates the underlying structural risk: the UK's dependence on imported petrochemical products for essential healthcare supplies. Addressing that requires policy action, investment in domestic polymer conversion capacity and a willingness to pay the higher unit costs that onshore manufacturing entails. For now, the immediate priority for operators is to protect supply continuity and manage margin erosion through a disruption whose duration remains uncertain.